Immunoconjugates: lessons from animal models.
Monoclonal antibody-mediated cancer therapy has evolved through a challenging chain of problems and solutions. The very limited therapeutic success obtained with unarmed monoclonal antibodies has increased the interest in different antibody-based targeting strategies, and numerous preclinical and even clinical studies with immunoconjugates have now been conducted. We comment here on the messages implicit in a recent report on a doxorubicin-anti-carcinoma antibody conjugate and from several other studies.
Canevari
S
S
Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy.
Colombatti
M
M
Colnaghi
M I
MI
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000627:therapeutic use; D018796:Immunoconjugates / Q000627:therapeutic use*; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy*; D051381:Rats
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D004317:Doxorubicin